Credit Suisse analyst Judah Frommer assumed coverage of Ascendis Pharma with a Neutral rating and $89 price target. The analyst made no changes to the firm’s prior rating, target price, or estimates.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
- Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
- Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
- Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
- Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023